AKIGAI was founded with one purpose: to accelerate the development of EGFR inhibitors for the treatment of neuropathic pain, so that safe and effective options may become broadly available.
At present, our medicines are not yet approved or reimbursed for these conditions. Still, we are convinced that an effective treatment can be developed.
To make our medicines available broadly to patients as quickly as possible, we are focused on enrolling and conducting the clinical trials necessary to gain regulatory approvals. We believe this approach will serve patients who could be helped by the therapies we are developing.
We are deeply moved by the suffering faced by people living with neuropathic pain. The relief we have already witnessed in some patients is both a motivation and a responsibility for us to continue this work.
At this time, AKIGAI is not offering Expanded Access to AKI-007. Clinical trials are being planned, and when ready, we will share details here, including who can participate, trial centers, contact information, and timelines.